What is the WAC for Jardiance?
The wholesale acquisition cost (WAC) for Jardiance (empagliflozin), a Boehringer Ingelheim diabetes drug, is $597.94 for a 30-tablet bottle of 10 mg strength and $597.94 for 25 mg strength (as of latest pricing data).[1]
How does Jardiance pricing compare to other SGLT2 inhibitors?
Jardiance WAC exceeds Farxiga (dapagliflozin) at $557.10 for 30 tablets of 10 mg, but trails Invokana (canagliflozin) at $638.50 for 30 tablets of 100 mg. These prices reflect list costs before discounts, rebates, or insurance.[1][2]
Who manufactures Jardiance and when do patents expire?
Boehringer Ingelheim and Eli Lilly co-market Jardiance. Key U.S. patents expire in 2028 (empagliflozin compound) with pediatric exclusivity to 2031, though challenges from generics like Viatris could accelerate entry.[3]
What do patients pay after insurance or discounts?
Net prices drop sharply: Medicare Part D pays around $480 monthly after rebates, while GoodRx coupons bring cash prices to $550-$600 for 30 tablets. Patient assistance caps costs at $10/month for eligible uninsured.[1][4]
Why does WAC matter for drugs like Jardiance?
WAC sets the manufacturer list price for wholesalers, serving as a benchmark before pharmacy benefit manager negotiations reduce it by 40-70%. It influences Medicare negotiations under the Inflation Reduction Act.[2]
[1]: DrugPatentWatch.com - Jardiance Pricing
[2]: IQVIA National Drug Pricing
[3]: FDA Orange Book - Empagliflozin Patents
[4]: GoodRx - Jardiance Prices